Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.

Friese CR, Pini TM, Li Y, Abrahamse PH, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Hawley ST, Katz SJ, Griggs JJ.

Breast Cancer Res Treat. 2013 Apr;138(3):931-9. doi: 10.1007/s10549-013-2499-9. Epub 2013 Mar 31.

2.

Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.

Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Mujahid MS, Friese CR, Salem B, Abrahamse PH, Katz SJ.

J Clin Oncol. 2012 Sep 1;30(25):3058-64. doi: 10.1200/JCO.2012.41.9564. Epub 2012 Aug 6.

3.

Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.

Kuba S, Ishida M, Nakamura Y, Taguchi K, Ohno S.

Breast Cancer. 2016 Jan;23(1):128-33. doi: 10.1007/s12282-014-0540-4. Epub 2014 Jun 17.

PMID:
24934610
4.

Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?

Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A, Lawrenson R.

Breast. 2015 Feb;24(1):62-7. doi: 10.1016/j.breast.2014.11.011. Epub 2014 Dec 5.

PMID:
25486877
5.

Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries.

Jagsi R, Pottow JA, Griffith KA, Bradley C, Hamilton AS, Graff J, Katz SJ, Hawley ST.

J Clin Oncol. 2014 Apr 20;32(12):1269-76. doi: 10.1200/JCO.2013.53.0956. Epub 2014 Mar 24.

6.

Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.

Jagsi R, Griffith KA, Kurian AW, Morrow M, Hamilton AS, Graff JJ, Katz SJ, Hawley ST.

J Clin Oncol. 2015 May 10;33(14):1584-91. doi: 10.1200/JCO.2014.58.5885. Epub 2015 Apr 6.

7.

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.

Camacho FT, Tan X, Alcalá HE, Shah S, Anderson RT, Balkrishnan R.

Medicine (Baltimore). 2017 Jun;96(24):e7147. doi: 10.1097/MD.0000000000007147.

8.

The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis.

Lantz PM, Mujahid M, Schwartz K, Janz NK, Fagerlin A, Salem B, Liu L, Deapen D, Katz SJ.

Am J Public Health. 2006 Dec;96(12):2173-8. Epub 2006 Oct 31.

9.

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

Güth U, Myrick ME, Schötzau A, Kilic N, Schmid SM.

Breast Cancer Res Treat. 2011 Oct;129(3):799-807. doi: 10.1007/s10549-011-1668-y. Epub 2011 Jul 13.

PMID:
21750963
10.

The evolving role of endocrine therapy for early stage breast cancer.

Manders JB, Gradishar WJ.

Breast Cancer. 2005;12(2):62-72. Review. No abstract available.

11.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

12.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
13.

Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.

Booth CM, Pater JL, Goss PE.

Cancer. 2007 May 1;109(9):1927-8; author reply 1928. No abstract available.

14.

Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.

Wengström Y, Aapro M, Leto di Priolo S, Cannon H, Georgiou V.

Breast. 2007 Oct;16(5):462-8. Epub 2007 Apr 20.

PMID:
17449249
15.
16.

[Adjuvant treatment of breast cancer. Endocrine therapy].

Mouridsen HT, Andersen J.

Ugeskr Laeger. 2007 Sep 10;169(37):3072-6. Danish.

PMID:
17877951
17.

Selecting adjuvant endocrine therapy for breast cancer.

Eneman JD, Wood ME, Muss HB.

Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review.

18.

A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.

Yu KD, Zhou Y, Liu GY, Li B, He PQ, Zhang HW, Lou LH, Wang XJ, Wang S, Tang JH, Liu YH, Wang X, Jiang ZF, Ma LW, Gu L, Cao MZ, Zhang QY, Wang SM, Su FX, Zheng H, Li HY, Tang LL, Sun SR, Liu JP, Shao ZM, Shen ZZ.

Breast Cancer Res Treat. 2012 Jul;134(1):307-13. doi: 10.1007/s10549-012-2059-8. Epub 2012 Apr 12.

PMID:
22527106
19.

Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting.

Morales L, Neven P, Paridaens R.

Curr Opin Oncol. 2005 Nov;17(6):559-65. Review.

PMID:
16224233
20.

Optimal adjuvant endocrine therapy for early breast cancer.

Stuart-Harris R, Davis A.

Womens Health (Lond). 2010 May;6(3):383-98. doi: 10.2217/whe.10.25. Review.

PMID:
20426605

Supplemental Content

Support Center